-
Product Insights
Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
 Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy. The Hairy Cell Leukemia pipeline drugs market research report outlays comprehensive information on the Hairy Cell Leukemia targeted therapeutics, complete with analysis...
-
Product Insights
Pandemic Influenza – Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Pandemic Influenza - Global Clinical Trials Review, H2, 2021" provides an overview of Pandemic Influenza Clinical trials scenario. This report provides top line data relating to the clinical trials on Pandemic Influenza. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides...
-
Product Insights
Wheezing Disease – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Wheezing Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Wheezing Clinical trials scenario. This report provides top line data relating to the clinical trials on Wheezing. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
Dermatomyositis Disease – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Dermatomyositis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Dermatomyositis Clinical trials scenario. This report provides top line data relating to the clinical trials on Dermatomyositis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
Pandemic Influenza – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Pandemic Influenza Global Clinical Trials Review, H2, 2020" provides an overview of Pandemic Influenza Clinical trials scenario. This report provides top line data relating to the clinical trials on Pandemic Influenza. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Wheezing Disease – Global Clinical Trials Review, H1, 2020
GlobalData's clinical trial report, “Wheezing Global Clinical Trials Review, H1, 2020" provides an overview of Wheezing Clinical trials scenario. This report provides top line data relating to the clinical trials on Wheezing. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
OpportunityAnalyzer: Bladder Cancer – Opportunity Analysis and Forecasts to 2025
The bladder cancer market in the seven major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, and Japan) has remained largely unchanged in the past 10-20 years. However, significant expansion is expected starting in 2016, with the introduction of several new therapies that are projected to fuel market growth. In addition, bladder cancer has a robust early-stage pipeline that will contribute to market growth during the forecast period. Currently, the bladder cancer market is dominated by generic chemotherapy and immunotherapy....
-
Sector Analysis
OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025
Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point the prognosis is poor. Current standard of care therapies focus on debulking surgery and platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard. The majority of patients respond well to initial first-line therapy and enter into remission,...
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals
The pharmaceutical and healthcare industry reported an increase in the number of deals and a decrease in deal values in March 2017. The industry reported 378 deals worth USD13.6 billion in March 2017, compared to 303 deals worth USD19.4 billion in February 2017. The oncology therapeutics market remained at the top in deal activity in March 2017 with 149 deals. In second place, immunology therapeutics market reported 74 deals. Licensing agreements in pharmaceutical and healthcare industry registered a decrease in...
-
Sector Analysis
PharmaPoint: Rheumatoid Arthritis – Global Drug Forecast and Market Analysis to 2025
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over six million individuals in the 8MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, and Australia) and this prevalence is expected to grow to just shy of 7 million individuals by 2025. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly...
-
Sector Analysis
OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2024
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. NHLs are further categorized into indolent or aggressive prognostic subtypes, which further influence the outcomes and treatment decisions. Patients diagnosed with indolent NHLs (follicular lymphoma [FL] or marginal zone lymphoma [MZL]) can achieve a median survival of 10 to 20 years, and relative...
-
Sector Analysis
OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) – Opportunity Analysis and Forecasts to 2024
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) pneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. RSV can cause upper respiratory tract infections (the common cold) and is the most important cause of lower respiratory tract infections, such as bronchiolitis and pneumonia, in infants. RSV is also an...
-
Product Insights
Head And Neck Cancer Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Head And Neck Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Head And Neck Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Head And Neck Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
PharmaPoint: Seasonal Influenza Vaccines – Global Drug Forecast and Market Analysis to 2025
Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection's rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza. Today, available vaccines include the older egg-based,...
-
Sector Analysis
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis – Global Drug Forecast and Market Analysis to 2025
Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. As a multisystem disorder, SLE is heterogeneous in nature—no two cases of lupus are alike—and can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The etiology of SLE and LN remains incompletely understood, but genetic and environmental factors have been shown to...
-
Track & Monitor
PharmSource – CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2018 Edition
This report is the 8th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.
-
Sector Analysis
Market Access, Pricing and Reimbursement of Oncology Medicines in the 5EU
Market access of oncology medicines is increasingly challenging due to the rising cost of new and innovative medicines, more stringent scientific and value assessments and economic pressures on national budgets and health systems. Although, 5EU markets have implemented patient access schemed to ensure early access to innovative oncology medicines with high unmet need, the increasing requirements for improved clinical benefits and better cost-effectiveness of medicines has resulted in more stringent pricing and reimbursement of medicines leading to access issues such...
-
Company Insights
Disruptor Profile: Cellink AB
Cellink AB (Cellink) is a 3Dbioprinter and a bioink company. It focuses on development of bioprinting technologies, which enable researchers to 3D print human organs and tissues for use in development of pharma and cosmetic treatments.
-
Sector Analysis
PharmaPoint: Healthcare-Associated Gram-Negative Infections – Global Drug Forecast and Market Analysis to 2026
Healthcare-associated infections (HAIs) are a major threat to patient safety, and place a substantial economic burden on healthcare systems. HAIs occur in hospitalized patients, and are not present at the time of admission. Acute care hospitals are the primary settings for contracting HAIs, with a high concentration occurring within non-nursery wards and intensive care units (ICUs).The most common types of HAIs are related to the use of invasive devices or surgical procedures, and fall into the following infection site categories:...
-
Sector Analysis
Hepatocellular Carcinoma: Competitive Landscape to 2026
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. It is the sixth most common type of cancer, accounts for around 90% of primary liver cancers, and is third most common cause of cancer mortality. HCC is particularly aggressive and has a poor survival rate (five-year survival <5%) and therefore remains an important public health issue worldwide. In Asia and Africa, factors for development include Hepatitis B and C infection, aflatoxin exposure (from crops), liver cirrhosis and hemochromatosis,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.